

To: [redacted] <[redacted]@astrazeneca.com>; [redacted] <[redacted]@rivm.nl>; [redacted] <[redacted]@rivm.nl>; [redacted] <[redacted]@astrazeneca.com>  
 Cc: [redacted] <[redacted]@astrazeneca.com>  
 From: [redacted]  
 Sent: Wed 2/10/2021 7:09:13 PM  
 Subject: RE: Ter info WHO SAGE recommendations on use of AZD1222 & persrelease long term supply  
 Received: Wed 2/10/2021 7:09:14 PM

Fijn dat je ons steeds zo snel op de hoogte brengt – Dank [redacted]

Met vriendelijke groet,

[redacted]

---

From: [redacted] <[redacted]@astrazeneca.com>  
 Sent: woensdag 10 februari 2021 19:36  
 To: [redacted] <[redacted]@rivm.nl>; [redacted] <[redacted]@rivm.nl>; [redacted] <[redacted]@rivm.nl>; [redacted] <[redacted]@rivm.nl>; [redacted] <[redacted]@rivm.nl>  
 Cc: [redacted] <[redacted]@astrazeneca.com>  
 Subject: Ter info WHO SAGE recommendations on use of AZD1222 & persrelease long term supply

Beste allen,

Zojuist ontvangen het laatste nieuws, ik stuur het graag ter info door:

*The WHO Strategic Advisory Group of Experts on Immunization (SAGE) has [just published its interim recommendations for the use of AZD1222](#).*

**Highlights from the WHO SAGE Recommendations:**

- **Age:** The vaccine is recommended for adults age 18 or older. WHO specifically recommends its use in people aged 65 or older, based on well-documented immune responses induced by the vaccine which suggest the vaccine is safe and efficacious in older persons, supported by vaccine impact modelling work.
- **Dosing:** WHO recommends a two dose regimen. While it notes that the vaccine label sets out an interval of 4-12 weeks,
- **Interval In between doses:** WHO recommends a dosing interval of 8-12 weeks, based on the observation that efficacy and immunogenicity increase with a longer inter-dose interval.
- **Elderly:** AZD1222 is recommended for use in elderly
- **New variants:** Use of the vaccine is recommended even if variants are present in a country, according to the WHO Prioritization Roadmap. It is recommended that countries conduct a benefit-risk assessment according to the local epidemiological situation, including the extent of circulating virus variants.

Daarnaast is er ook nog een persbericht uitgekomen over de voorgenomen uitbreiding van de productie faciliteit in Europa om op lange termijn de supply te kunnen garanderen. Heb het persbericht niet als PDF document dus ik verwijs jullie bij deze door naar de website voor info indien gewenst:

<https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-and-idt-biologika-sign-letter-of-intent-to-increase-covid-19-vaccine-manufacturing-in-europe-and-secure-long-term-supply-capacity.html>

Hartelijke groet, ook namens [redacted]

Met vriendelijke groet / Kind regards,

[redacted]

**AstraZeneca BV**

Bezoekadres: Prinses Beatrixlaan 582, 2595 BM Den Haag

T: [redacted] M: [redacted]

[redacted] <[redacted]@astrazeneca.com>  
[www.astrazeneca.nl](http://www.astrazeneca.nl)

Please consider the environment before printing this e-mail

This e-mail is intended solely for the use of the addressee and is not meant for distribution or disclosure outside AstraZeneca. The information in this e-mail may be personal or confidential. Any views or opinions presented do not necessarily represent those of AstraZeneca. Should you receive this message by mistake, please notify the sender immediately and delete this e-mail from your system without opening the attachment.